MedPath

MV-012-968

Generic Name
MV-012-968
Clinical Trials
Related News

A Study to Assess the Safety, Tolerability, and Immunogenicity of RSVpreF in Older Adults in Korea

Phase 3
Completed
Conditions
Respiratory Syncytial Virus
Interventions
Other: Placebo
First Posted Date
2024-09-19
Last Posted Date
2025-02-14
Lead Sponsor
Pfizer
Target Recruit Count
377
Registration Number
NCT06593587
Locations
🇰🇷

Inha University Hospital, Incheon, Incheon-gwangyeoksi [incheon], Korea, Republic of

🇰🇷

Jeonbuk National University Hospital, Jeonju-si, Jeonrabugdo, Korea, Republic of

🇰🇷

Chonnam National University Hospital, Gwangju-si, Kwangju-kwangyǒkshi, Korea, Republic of

and more 13 locations

SPECIAL INVESTIGATION FOR ABRYSVO IN INDIVIDUALS AGED 60 YEARS OR OLDER

Not yet recruiting
Conditions
Respiratory Syncytial Virus Infection
Interventions
First Posted Date
2024-08-09
Last Posted Date
2025-04-11
Lead Sponsor
Pfizer
Target Recruit Count
1100
Registration Number
NCT06546800
Locations
🇯🇵

Pfizer, Tokyo, Japan

SPECIAL INVESTIGATION FOR ABRYSVO IN PREGNANT WOMEN AND INFANTS

Active, not recruiting
Conditions
Respiratory Tract Infection
Interventions
First Posted Date
2024-07-01
Last Posted Date
2025-05-22
Lead Sponsor
Pfizer
Target Recruit Count
490
Registration Number
NCT06482099
Locations
🇯🇵

Pfizer, Tokyo, Japan

A Study to Learn About the Vaccine RSVpreF In Pregnant Participants With HIV and Their Infants

Phase 3
Active, not recruiting
Conditions
Respiratory Syncytial Virus
Interventions
Biological: Placebp
First Posted Date
2024-03-22
Last Posted Date
2025-04-11
Lead Sponsor
Pfizer
Target Recruit Count
343
Registration Number
NCT06325657
Locations
🇿🇦

Setshaba Research Centre, Tshwane, Gauteng, South Africa

🇿🇦

Synergy Biomed Research Institute, East London, Eastern CAPE, South Africa

🇿🇦

Josha Research, Bloemfontein, FREE State, South Africa

and more 11 locations
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy